Abstract |
A high performance liquid chromatographic (HPLC) procedure has been developed for the determination of cisplatin, based on the pre-column derivation of platinum(II) with reagent N,N'-bis(salicylidene)-1,2-propanediamine (H2SA2pn). The neutral platinum complex was extracted, concentrated in an organic solvent and then injected (5 microl) on a reverse phase HPLC column, Varian Micro-Pak SP C-18, 5 microm (150 mm x 4.0 mm i.d.). The complex was eluted isocratically using a ternary mixture of methanol/ acetonitrile/water (40/30/30, v/v/v) at a flow rate of 1.0 ml/min and was determined by a UV detector set at 254 nm after elution. A detection limit was found to be 4.0 ng per injection. The amounts of platinum in blood serum and urine of cancer patients after administration of cisplatin were observed in a range of 221-298 ng/ml and 43-97 ng/ml with relative standard deviation (R.S.D.) of 3.6-4.6% and 3.5-4.8%, respectively. Preliminary metabolism profiles of Pt concentrations in blood and urine from the patients were established.
|
Authors | Shah Nawaz Lanjwani, Renkang Zhu, Mohammad Yar Khuhawar, Zhifeng Ding |
Journal | Journal of pharmaceutical and biomedical analysis
(J Pharm Biomed Anal)
Vol. 40
Issue 4
Pg. 833-9
(Mar 03 2006)
ISSN: 0731-7085 [Print] England |
PMID | 16181764
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Chelating Agents
- Diamines
- Indicators and Reagents
- N,N'-bis(salicylidene)-1.2-propanediamine
- Schiff Bases
- Platinum
- Cisplatin
|
Topics |
- Antineoplastic Agents
(blood, therapeutic use, urine)
- Chelating Agents
- Chromatography, High Pressure Liquid
(methods)
- Cisplatin
(blood, therapeutic use, urine)
- Diamines
- Humans
- Indicators and Reagents
- Neoplasms
(blood, drug therapy, urine)
- Platinum
(blood, urine)
- Schiff Bases
- Spectrophotometry, Ultraviolet
|